Table 2.

Association between patients with different glycaemic status at baseline or time-dependent diabetes during follow-up and risk of subsequent multimorbidity cluster of cardiovascular disease and cancer^a

Variable	Cases/person-years	Incidence per 1000 person-years	Crude hazard ratio	95% confidence interval	P value	Adjusted hazard ratio	95% confidence interval	P value
Model 1
Normal glucose tolerance	18/14,394	1.25 (0.67–1.83)	Reference			Reference
Impaired glucose tolerance	45/14,174	3.17 (2.25–4.10)	2.7	1.60–4.78	< 0.001	3.28	1.83–5.87	< 0.001
Newly diagnosed type 2 diabetes	41/12,686	3.23 (2.24–4.22)	3.56	2.04–6.21	< 0.001	3.90	2.14–7.09	< 0.001
Model 2
Diabetes status (time-dependent)
Non-diabetes status	14/10,144	1.38 (0.66–2.10)	Reference			Reference
Diabetes status	90/31,110	2.89 (2.30–3.49)	2.37	1.46–3.83	< 0.001	2.55	1.51–4.31	< 0.001

Adjusted for age, sex, smoking status, obesity status, hypertension status, hypoglycaemic drugs, lipid-lowering drugs, and antihypertensive drugs

^aAdditional model analysis which took IGT as reference group showed that the risk of multimorbidity cluster of CVD and cancer in diabetes group was not different with IGT group (HR = 1.21, 95% CI 0.78–1.87, P = 0.40) after a same adjustment